221 related articles for article (PubMed ID: 31852138)
1. Selection of patients with ovarian cancer who may show survival benefit from hyperthermic intraperitoneal chemotherapy: A systematic review and meta-analysis.
Kim SI; Cho J; Lee EJ; Park S; Park SJ; Seol A; Lee N; Yim GW; Lee M; Lim W; Song G; Chang SJ; Kim JW; Kim HS
Medicine (Baltimore); 2019 Dec; 98(50):e18355. PubMed ID: 31852138
[TBL] [Abstract][Full Text] [Related]
2. Effects of CytoReductive surgery plus hyperthermic IntraPEritoneal chemotherapy (HIPEC) versus CytoReductive surgery for ovarian cancer patients: A systematic review and meta-analysis.
Wang Y; Ren F; Chen P; Liu S; Song Z; Ma X
Eur J Surg Oncol; 2019 Mar; 45(3):301-309. PubMed ID: 30786961
[TBL] [Abstract][Full Text] [Related]
3. Hyperthermic intraperitoneal chemotherapy (HIPEC) for the management of primary advanced and recurrent ovarian cancer: a systematic review and meta-analysis of randomized trials.
Filis P; Mauri D; Markozannes G; Tolia M; Filis N; Tsilidis K
ESMO Open; 2022 Oct; 7(5):100586. PubMed ID: 36116421
[TBL] [Abstract][Full Text] [Related]
4. Survival and complications of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in patients with intra-abdominal malignancies: A meta-analysis of randomized controlled trials.
Jian C; Mou H; Zhang Y; Fan Q; Ou Y
Front Pharmacol; 2023; 14():1094834. PubMed ID: 36969856
[No Abstract] [Full Text] [Related]
5. The prognosis impact of hyperthermic intraperitoneal chemotherapy (HIPEC) plus cytoreductive surgery (CRS) in advanced ovarian cancer: the meta-analysis.
Zhang G; Zhu Y; Liu C; Chao G; Cui R; Zhang Z
J Ovarian Res; 2019 Apr; 12(1):33. PubMed ID: 30995948
[TBL] [Abstract][Full Text] [Related]
6. Treatment of microscopic disease with hyperthermic intraoperative intraperitoneal chemotherapy after complete cytoreduction improves disease-free survival in patients with stage IIIC/IV ovarian cancer.
Cascales-Campos PA; Gil J; Gil E; Feliciangeli E; González-Gil A; Parrilla JJ; Parrilla P
Ann Surg Oncol; 2014 Jul; 21(7):2383-9. PubMed ID: 24599409
[TBL] [Abstract][Full Text] [Related]
7. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in Asian patients: 100 consecutive patients in a single institution.
Teo MC; Tan GH; Tham CK; Lim C; Soo KC
Ann Surg Oncol; 2013 Sep; 20(9):2968-74. PubMed ID: 23504144
[TBL] [Abstract][Full Text] [Related]
8. [Efficacy of 1 384 cases of peritoneal carcinomatosis underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy].
Yu Y; Li XB; Lin YL; Ma R; Ji ZH; Zhang YB; An SL; Liu G; Yang XJ; Li Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):230-239. PubMed ID: 34645167
[No Abstract] [Full Text] [Related]
9. Hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) with primary or secondary cytoreductive surgery in the treatment of advanced epithelial ovarian cancer.
Manzanedo I; Pereira F; Pérez-Viejo E; Serrano Á; Hernández-García M; Martínez-Torres B; Rihuete-Caro C; Calzas J; Cueto M
Minerva Ginecol; 2017 Apr; 69(2):119-127. PubMed ID: 27415829
[TBL] [Abstract][Full Text] [Related]
10. Cytoreduction (Peritonectomy Procedures) Combined with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Advanced Ovarian Cancer: Retrospective Italian Multicenter Observational Study of 511 Cases.
Di Giorgio A; De Iaco P; De Simone M; Garofalo A; Scambia G; Pinna AD; Verdecchia GM; Ansaloni L; Macrì A; Cappellini P; Ceriani V; Giorda G; Biacchi D; Vaira M; Valle M; Sammartino P
Ann Surg Oncol; 2017 Apr; 24(4):914-922. PubMed ID: 27896512
[TBL] [Abstract][Full Text] [Related]
11. [Meta analysis of whether cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy can improve survival in patients with colorectal cancer peritoneal metastasis].
Liu D; Wang H; Yuan ZX; Chen WW; Wu ZJ; Liu XX; Luo J; Chu LL; Li Y; Cai J
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):256-263. PubMed ID: 34645170
[No Abstract] [Full Text] [Related]
12. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Gastric Cancer with Peritoneal Carcinomatosis: Multicenter Study of Spanish Group of Peritoneal Oncologic Surgery (GECOP).
Manzanedo I; Pereira F; Rihuete Caro C; Pérez-Viejo E; Serrano Á; Gutiérrez Calvo A; Regueira FM; Casado-Adam Á; Cascales-Campos PA; Arteaga X; García-Fadrique A; Gómez Sanz R; López García A; Zozaya G; Arjona Á; Gil Martínez J
Ann Surg Oncol; 2019 Aug; 26(8):2615-2621. PubMed ID: 31115852
[TBL] [Abstract][Full Text] [Related]
13. Peritoneal Carcinomatosis of Rare Ovarian Origin Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: A Multi-Institutional Cohort from PSOGI and BIG-RENAPE.
Mercier F; Bakrin N; Bartlett DL; Goere D; Quenet F; Dumont F; Heyd B; Abboud K; Marolho C; Villeneuve L; Glehen O; ;
Ann Surg Oncol; 2018 Jun; 25(6):1668-1675. PubMed ID: 29637438
[TBL] [Abstract][Full Text] [Related]
14. Effect of hyperthermic intraperitoneal chemotherapy in combination with cytoreductive surgery on the prognosis of patients with colorectal cancer peritoneal metastasis: a systematic review and meta-analysis.
Li J; Wang AR; Chen XD; Zhang YX; Pan H; Li SQ
World J Surg Oncol; 2022 Jun; 20(1):200. PubMed ID: 35701802
[TBL] [Abstract][Full Text] [Related]
15. Effect of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy on relapse pattern in primary epithelial ovarian cancer: a propensity score based case-control study.
Ceresoli M; Verrengia A; Montori G; Busci L; Coccolini F; Ansaloni L; Frigerio L
J Gynecol Oncol; 2018 May; 29(3):e53. PubMed ID: 29533028
[TBL] [Abstract][Full Text] [Related]
16. Hyperthermic Intraperitoneal Chemotherapy (HIPEC): An Overview of the Molecular and Cellular Mechanisms of Actions and Effects on Epithelial Ovarian Cancers.
Lim PQ; Han IH; Seow KM; Chen KH
Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077477
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of hyperthermic intraperitoneal chemotherapy in patients with epithelial ovarian cancer: a meta-analysis.
Wu Q; Wu Q; Xu J; Cheng X; Wang X; Lu W; Li X
Int J Hyperthermia; 2019; 36(1):562-572. PubMed ID: 31137989
[No Abstract] [Full Text] [Related]
18. Primary Tumor Sidedness is Predictive of Survival in Colon Cancer Patients Treated with Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy: A US HIPEC Collaborative Study.
Kotha NV; Baumgartner JM; Veerapong J; Cloyd JM; Ahmed A; Grotz TE; Leiting JL; Fournier K; Lee AJ; Dineen SP; Dessureault S; Clarke C; Mogal H; Zaidi MY; Russell MC; Patel SH; Sussman JJ; Dhar V; Lambert LA; Hendrix RJ; Abbott DE; Pokrzywa C; Lafaro K; Lee B; Greer JB; Fackche N; Lowy AM; Kelly KJ
Ann Surg Oncol; 2019 Jul; 26(7):2234-2240. PubMed ID: 31016486
[TBL] [Abstract][Full Text] [Related]
19. Cytoreductive Surgery With or Without HIPEC After Neoadjuvant Chemotherapy in Ovarian Cancer: A Phase 3 Clinical Trial.
Antonio CCP; Alida GG; Elena GG; Rocío GS; Jerónimo MG; Luis ARJ; Aníbal ND; Francisco BV; Jesús GRÁ; Pablo RR; José GM
Ann Surg Oncol; 2022 Apr; 29(4):2617-2625. PubMed ID: 34812982
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of Hyperthermic Intraperitoneal Chemotherapy Associated with Cytoreductive Surgery in the Treatment of Advanced Ovarian Cancer: Systematic Review and Meta-Analysis.
Llueca M; Ibañez MV; Climent MT; Serra A; Llueca A;
J Pers Med; 2023 Jan; 13(2):. PubMed ID: 36836494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]